TMO · Thermo Fisher Scientific Inc.
$588.29
-7.60 (-1.28%)
At close · Aug 14
Market Cap
$217.52B
Shares
369.75M
Thermo Fisher Scientific Inc. Earnings Call Transcripts
Every quarterly earnings call for Thermo Fisher Scientific Inc. (TMO) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲14.4%
$10.68B
$1.50B
'22 Q3
22-10-26
▲7%
$11.45B
$1.57B
'22 Q4
23-02-01
▼9.4%
$10.71B
$1.29B
'23 Q1
23-04-26
▼2.6%
$10.69B
$1.36B
'23 Q2
23-07-26
▼1%
$10.57B
$1.70B
'23 Q3
23-10-25
▼4.9%
$10.89B
$1.65B
'23 Q4
24-01-31
▼3.4%
$10.35B
$1.33B
'24 Q1
24-04-24
▼1.4%
$10.54B
$1.55B
'24 Q2
24-07-24
▲0.2%
$10.60B
$1.63B
'24 Q3
24-10-23
▲4.7%
$11.39B
$1.83B
'24 Q4
25-01-30
▲0.2%
$10.36B
$1.51B
'25 Q1
25-04-23
▲3%
$10.86B
$1.62B
'25 Q2
25-07-23
▲4.9%
$11.12B
$1.62B
'25 Q3
25-10-22
▲7.2%
$12.21B
$1.96B
'25 Q4
26-01-29
▲6.2%
$11.01B
$1.65B
'26 Q1
26-04-23
LATEST
▲10.5%
$11.99B
$1.74B
'26 Q2
26-07-23
Earnings call
FY26 · Q2
2026-07-23
Thermo Fisher Scientific Q2 2026 Earnings Call
Confident tone
Quarterly financial results
End market performance
Bioproduction and clinical research (PPD/Clario)
Revenue
$11.99B
▲ 10.5% YoY Diluted EPS
$4.68
▲ 9.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Capital Markets Day
Investor event
2026-05-20
Thermo Fisher Scientific Inc. 2026 Investor Day
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-04-23
Thermo Fisher Scientific Inc. Q1 FY2026 Earnings Call
Positive tone
Strategic collaborations and M&A
Quarterly financial results
End market performance
Revenue
$11.01B
▲ 6.2% YoY Diluted EPS
$4.43
▲ 11.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-01-29
Thermo Fisher Scientific Inc. Q4 FY2025 Earnings Call
Confident tone
Pharma and Biotech End Market
2026 Guidance and Outlook
Accelerator Drug Development / CDMO and CRO
Revenue
$12.21B*
▲ 7.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-10-22
Thermo Fisher Scientific Inc. Q3 FY2025 Earnings Call
Confident tone
Strategic Collaboration with OpenAI
End Markets
PPD and Clinical Research Services
Revenue
$11.12B
▲ 4.9% YoY Diluted EPS
$4.27
▲ 0.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-07-23
Thermo Fisher Scientific Inc. Q2 FY2025 Earnings Call
Positive tone
Tariffs and policy environment
Pharma and biotech end market
Trusted partner status and PPI Business System
Revenue
$10.86B
▲ 3% YoY Diluted EPS
$4.28
▲ 5.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-04-23
Thermo Fisher Scientific Inc. Q1 FY2025 Earnings Call
Positive tone
Q1 strong financial execution
Bioproduction and pharma services demand
High-impact innovation and new products
Revenue
$10.36B
▲ 0.2% YoY Diluted EPS
$3.98
▲ 15% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-01-30
Thermo Fisher Scientific Inc. Q4 FY2024 Earnings Call
Confident tone
Q4 and full-year financial results
Pharma services and Accelerator Drug Development
China business and environment
Revenue
$11.39B*
▲ 4.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-23
Thermo Fisher Scientific Inc. Q3 FY2024 Earnings Call
Positive tone
Clinical research (PPD) and CRO trends
Pharma and biotech end market
Quarterly financial performance and EPS guidance raise
Revenue
$10.60B
▲ 0.2% YoY Diluted EPS
$4.25
▼ 3.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-07-24
Thermo Fisher Scientific Inc. Q2 FY2024 Earnings Call
Confident tone
PPI business system and operational execution
End market performance
Customer partnerships and commercial expansion
Revenue
$10.54B
▼ 1.4% YoY Diluted EPS
$4.04
▲ 15.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-04-24
Thermo Fisher Scientific Inc. Q1 FY2024 Earnings Call
Confident tone
Quarterly financial performance
China and Biosecure Act risk
Raised guidance
Revenue
$10.35B
▼ 3.4% YoY Diluted EPS
$3.46
▲ 4.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-01-31
Thermo Fisher Scientific Inc. Q4 FY2023 Earnings Call
Positive tone
Q4 and full year financial results
PPI business system and operational discipline
China market outlook and Biosecure Act
Revenue
$10.89B*
▼ 4.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-10-25
Thermo Fisher Scientific Inc. Q3 FY2023 Earnings Call
Revenue
$10.57B
▼ 1% YoY Diluted EPS
$4.42
▲ 16.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-07-26
Thermo Fisher Scientific Inc. Q2 FY2023 Earnings Call
Revenue
$10.69B
▼ 2.6% YoY Diluted EPS
$3.51
▼ 16.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-04-26
Thermo Fisher Scientific Inc. Q1 FY2023 Earnings Call
Revenue
$10.71B
▼ 9.4% YoY Diluted EPS
$3.32
▼ 40.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-01
Thermo Fisher Scientific Inc. Q4 FY2022 Earnings Call
Revenue
$11.45B*
▲ 7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-10-26
Thermo Fisher Scientific Inc. Q3 FY2022 Earnings Call
Revenue
$10.68B
▲ 14.4% YoY Diluted EPS
$3.79
▼ 20.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-07-28
Thermo Fisher Scientific Inc. Q2 FY2022 Earnings Call
Revenue
$10.97B
▲ 18.3% YoY Diluted EPS
$4.22
▼ 8.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-04-28
Thermo Fisher Scientific Inc. Q1 FY2022 Earnings Call
Revenue
$11.82B
▲ 19.3% YoY Diluted EPS
$5.61
▼ 4.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-02
Thermo Fisher Scientific Inc. Q4 FY2021 Earnings Call
Revenue
$10.70B*
▲ 1.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-10-27
Thermo Fisher Scientific Inc. Q3 FY2021 Earnings Call
Revenue
$9.33B
▲ 9.5% YoY Diluted EPS
$4.79
▼ 1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-07-28
Thermo Fisher Scientific Inc. Q2 FY2021 Earnings Call
Revenue
$9.27B
▲ 34.1% YoY Diluted EPS
$4.61
▲ 59% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-04-29
Thermo Fisher Scientific Inc. Q1 FY2021 Earnings Call
Revenue
$9.91B
▲ 59% YoY Diluted EPS
$5.88
▲ 198.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-01
Thermo Fisher Scientific Inc. Q4 FY2020 Earnings Call
Revenue
$10.55B*
▲ 54.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-10-21
Thermo Fisher Scientific Inc. Q3 FY2020 Earnings Call
Revenue
$8.52B
▲ 35.9% YoY Diluted EPS
$4.84
▲ 157.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-07-06
Thermo Fisher Scientific Inc. Q2 FY2020 Earnings Call
Revenue
$6.92B
▲ 9.5% YoY Diluted EPS
$2.90
▲ 4.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-04-06
Thermo Fisher Scientific Inc. Q1 FY2020 Earnings Call
Revenue
$6.23B
▲ 1.7% YoY Diluted EPS
$1.97
▼ 2.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-01-30
Thermo Fisher Scientific Inc. Q4 FY2019 Earnings Call
Revenue
$6.83B
▲ 4.9% YoY Diluted EPS
$2.49
▲ 12.2% YoY Gross margin
44.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–28 of 28 earnings calls
Key facts
CIK
97745
CUSIP
883556102
13F (30d)
2250 filings
2188 filers
Visit website
Investor relations